You'd think folks who've had knee replacement surgery -- finally able to walk and exercise without pain -- would lose weight instead of put on pounds, but surprisingly that's not the case, according to a University of Delaware study. Researchers Joseph Zeni and Lynn Snyder-Mackler in the Department of Physical Therapy in UD's College of Health Sciences found that patients typically drop weight in the first few weeks after total knee arthroplasty (TKA), but then the number on the scale starts creeping upward, with an average weight gain of 14 pounds in two years. The study, which was sponsored by the National Institutes of Health, is reported in the Jan.
Investigators have identified a biomarker that could help doctors select patients with rheumatoid arthritis who will benefit from therapy with drugs such as Enbrel, a tumor necrosis factor (TNF)-antagonist drug. The study, led by researchers at Hospital for Special Surgery in collaboration with rheumatologists at University of Southern California, appears in the February issue of the journal Arthritis & Rheumatism. "While our study was performed on a relatively small group of patients and will need to be confirmed in a larger cohort, the data are promising and may be clinically significant for the medical management of patients, " said Mary K. Crow, M.
A recent study by researchers from the Cleveland Clinic found that the overall mortality rate in the U.S. for all pediatric patients with rheumatic diseases was not worse than the age and sex-adjusted population. Furthermore, mortality rates were significantly lower than reported in previous studies of rheumatic diseases and conditions that are associated with increased mortality. Details of the study appear in the February issue of Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) estimates that 300, 000 children in the U.S. suffer from some form of arthritis or rheumatic disease.
A recent study by researchers from the University of Pittsburgh found that workers with rheumatoid arthritis (RA) were comparable to non-impaired individuals in keyboarding speed. Individuals who were trained in touch typing demonstrated faster typing speeds than those using a visually-guided ("hunt and peck") method, regardless of impairment. Researchers also noted slightly impaired mouse skills in workers with RA. Results of this study appear in the February issue of Arthritis Care & Research, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology. According to the U.S. Census Bureau the number of workers using computers increased from 46% in 1993 to 56% in 2003 with figures expected to continue climbing higher.
European Commission Approves Orencia R Abatacept In Combination With Methotrexate For Children With Moderate To Severe pJIA
Bristol-Myers Squibb Company (NYSE: BMY) announced that on 20 January 2010, the European Commission approved ORENCIA ® (abatacept) in combination with methotrexate for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (pJIA) in paediatric patients six years of age and older who have had an insufficient response to other DMARDS, including at least one TNF inhibitor.1 Disease-modifying treatment options for children with pJIA have been extremely limited to date. ORENCIA, in combination with methotrexate (MTX), offers another treatment option for children six years of age and older with pJIA, filling an unmet need.
Researchers from University Hospital in Umea, Sweden, have identified several cytokines, cytokine-related factors, and chemokines that increase significantly prior to rheumatoid arthritis (RA) disease onset. These findings confirm those of earlier studies which suggest that the risk of developing RA can be predicted and disease progression may be prevented. Complete findings of this study are published in the February issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology. Rheumatoid arthritis is a chronic autoimmune disease characterized by joint inflammation involving the synovial (lubricating fluid of the joints) tissue and eventually leading to destruction of cartilage and bone.
The links between autoimmune diseases, infections, genetics and the environment are complex and mysterious. Why are people who live near airports more susceptible to autoimmune diseases like rheumatoid arthritis and lupus? How do hormones in meat trigger the onset of a disease? Our immediate environment interacts with our genetic programming and can determine if we will succumb to an autoimmune disease, says rheumatologist Prof. Michael Ehrenfeld of Tel Aviv University's Sackler School of Medicine, who is seeking to unravel those mysteries. Prof. Ehrenfeld recently published a report in Autoimmune Reviews on how "Spondylo-arthropathies, " a group of common inflammatory rheumatic disorders, appear to be triggered by environmental factors.
Final draft guidance published today (Thursday 21st January 2010) by the National Institute for Health and Clinical Excellence (NICE) will enable another therapy to be considered for some people in England, Wales and Northern Ireland suffering with rheumatoid arthritis. In the draft, certolizumab pegol is now recommended as a treatment option for some patients with the disease. Rheumatoid arthritis (RA) is a long-term disease in which joints in the body become inflamed, causing pain, swelling and stiffness. It often affects the small joints of the hands and the feet, and usually both sides equally and symmetrically. Around 400, 000 people in the UK have RA and people of all ages can develop the disease.
Researchers at Geisinger Medical Center recently received funding totaling more than $44, 000 from a Geisinger Health System (GHS) - NYU Langone Medical Center (NYULMC) collaborative project focusing on personalized healthcare. The grant, titled "Expanding Comparative Effectiveness Research in Orthopedics by Capturing Uniform Measures of Patient-Reported Functional Outcomes at Two Institutions", will permit Geisinger to administer electronic questionnaires to patients with osteoarthritis (OA) via new, touch-screen monitors in its orthopaedic clinics. Results from these questionnaires will allow physicians to track patient-reported outcomes, which are critical in developing evidence-based protocols in OA management.
MorphoSys Enrolls First Patient In Phase 1b 2a Clinical Trial For MOR103 Program In Rheumatoid Arthritis
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced that it has enrolled the first patient in its Phase 1b/2a clinical trial of its lead drug MOR103. The Company's lead development program, MOR103, is a fully human HuCAL antibody directed against GM-CSF (granulocyte macrophage-colony stimulating factor), being developed in the area of inflammatory diseases, such as rheumatoid arthritis (RA), where current treatment options are inadequate. "We are very pleased that our Phase 1b/2a study in patients with rheumatoid arthritis has now started according to plan, " commented Dr. Arndt Schottelius, Chief Development Officer. "This is an important step for MorphoSys, since we will test an antibody from our growing proprietary pipeline for the first time in patients.